Spots Global Cancer Trial Database for RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
Official Title: Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)
Study ID: NCT06155136
Conditions
Interventions
Study Description
Brief Summary: The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
Detailed Description: The objectives on patients still alive one year after the first cycle of nal-IRI : * Characterize mPDAC patient population according to their demographics * Identify PDAC treatment by line of treatment from diagnosis to last treatment * Explore prognostic factors of longer Overall Survival (OS) and Progression Free Survivor (PFS) among mPDAC patients showing long-term Survival
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum der Universität München, - Anstalt des öffentlichen Rechts -, Munich, , Germany
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
